{"protocolSection": {"identificationModule": {"nctId": "NCT00611884", "orgStudyIdInfo": {"id": "NN1250-1836"}, "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes", "officialTitle": "A 16 Week Randomised, Open-labelled, Four-armed, Treat-to-target, Parallel-group Trial Comparing SIBA D Once Daily, SIBA E Once Daily, SIBA D Monday, Wednesday and Friday and Insulin Glargine Once Daily, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment"}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-29", "studyFirstSubmitQcDate": "2008-02-08", "studyFirstPostDateStruct": {"date": "2008-02-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-16", "resultsFirstSubmitQcDate": "2015-10-16", "resultsFirstPostDateStruct": {"date": "2015-11-16", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2009-11-09", "dispFirstSubmitQcDate": "2009-11-09", "dispFirstPostDateStruct": {"date": "2009-11-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-19", "lastUpdatePostDateStruct": {"date": "2017-03-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 245, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "SIBA (D)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin degludec", "Drug: metformin"]}, {"label": "SIBA (E)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin degludec", "Drug: metformin"]}, {"label": "SIBA (D) M, W, F", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin degludec", "Drug: metformin"]}, {"label": "IGlar", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: insulin glargine", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "insulin glargine", "description": "Treat-to-target dose titration scheme, s.c. injection.", "armGroupLabels": ["IGlar"]}, {"type": "DRUG", "name": "insulin degludec", "description": "Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily", "armGroupLabels": ["SIBA (D)"]}, {"type": "DRUG", "name": "insulin degludec", "description": "Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily", "armGroupLabels": ["SIBA (E)"]}, {"type": "DRUG", "name": "insulin degludec", "description": "Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly", "armGroupLabels": ["SIBA (D) M, W, F"]}, {"type": "DRUG", "name": "metformin", "description": "Tablets, 1500-2000 mg/day", "armGroupLabels": ["IGlar", "SIBA (D)", "SIBA (D) M, W, F", "SIBA (E)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline in HbA1c after 16 weeks of treatment", "timeFrame": "Week 0, Week 16"}], "secondaryOutcomes": [{"measure": "Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)", "description": "Mean of SMPG after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, before bedtime, at 4 am and before breakfast.", "timeFrame": "Week 16"}, {"measure": "Rate of Major and Minor Hypoglycaemic Episodes", "description": "Rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Rate of Nocturnal Major and Minor Hypoglycaemic Episodes", "description": "Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 05:59 (included).", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Rate of Treatment Emergent Adverse Events (AEs)", "description": "Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)", "description": "Mean values at Week -4 and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)", "description": "Mean values at Week -4 and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Serum Creatinine", "description": "Mean values at Week -4 and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Vital Signs: Diastolic Blood Pressure (BP)", "description": "Mean values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Vital Signs: Systolic Blood Pressure (BP)", "description": "Mean values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Vital Signs: Pulse", "description": "Mean values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Physical Examination", "description": "Physical examination was performed at screening (Week -4), randomisation (Week 0) and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.", "timeFrame": "Week -4, Week 0, Week 8, Week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)\n* Insulin na\u00efve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximeum 14 days within the last 3 months)\n* Treatment with one or two oral anti-diabetic drug (OADs): metformin, sulphonylurea (SU) (or other insulin secretagogue e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 months at a stable maximally tolerated dose or at least half maximally allowed dose according to the summary of product characteristics (SPC) or locally approved PI\n* HbA1c 7.0-11.0 % (both inclusive)\n* Body Mass Index (BMI) 23-42 kg/m\\^2 \\[lb/in\\^2 x 703\\] (both inclusive)\n\nExclusion Criteria:\n\n* Metformin contraindication according to local practice\n* Thiazolidinedione (TZD) treatment within previous three months prior to visit 1\n* Any systemic treatment with products which in the Investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) three months prior to randomisation\n* Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system (except for conditions associated with type 2 diabetes) that, in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial drug", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Inglewood", "state": "California", "zip": "90301", "country": "United States", "geoPoint": {"lat": 33.96168, "lon": -118.35313}}, {"facility": "Novo Nordisk Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novo Nordisk Investigational Site", "city": "Redlands", "state": "California", "zip": "92374", "country": "United States", "geoPoint": {"lat": 34.05557, "lon": -117.18254}}, {"facility": "Novo Nordisk Investigational Site", "city": "Spring Valley", "state": "California", "zip": "91978", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "Novo Nordisk Investigational Site", "city": "Jacksonville", "state": "Florida", "zip": "32204", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Novo Nordisk Investigational Site", "city": "Idaho Falls", "state": "Idaho", "zip": "83404-7596", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60616", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novo Nordisk Investigational Site", "city": "Springfield", "state": "Illinois", "zip": "62711", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Novo Nordisk Investigational Site", "city": "Greensboro", "state": "North Carolina", "zip": "27408", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Novo Nordisk Investigational Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Novo Nordisk Investigational Site", "city": "Simpsonville", "state": "South Carolina", "zip": "29681", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Novo Nordisk Investigational Site", "city": "Newport News", "state": "Virginia", "zip": "23606", "country": "United States", "geoPoint": {"lat": 37.08339, "lon": -76.46965}}, {"facility": "Novo Nordisk Investigational Site", "city": "Renton", "state": "Washington", "zip": "98057", "country": "United States", "geoPoint": {"lat": 47.48288, "lon": -122.21707}}, {"facility": "Novo Nordisk Investigational Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53209", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cambridge", "state": "Ontario", "zip": "N1R 7L6", "country": "Canada", "geoPoint": {"lat": 43.3601, "lon": -80.31269}}, {"facility": "Novo Nordisk Investigational Site", "city": "Etobicoke", "state": "Ontario", "zip": "M9R 4E1", "country": "Canada", "geoPoint": {"lat": 43.65421, "lon": -79.56711}}, {"facility": "Novo Nordisk Investigational Site", "city": "Toronto", "state": "Ontario", "zip": "M5C 2T2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novo Nordisk Investigational Site", "city": "Toronto", "state": "Ontario", "zip": "M5T 3L9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hyderabad", "state": "Andhra Pradesh", "zip": "500082", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kochi", "state": "Kerala", "zip": "682041", "country": "India", "geoPoint": {"lat": 9.93988, "lon": 76.26022}}, {"facility": "Novo Nordisk Investigational Site", "city": "Mumbai", "state": "Maharashtra", "zip": "400012", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Novo Nordisk Investigational Site", "city": "Vellore", "state": "Tamil Nadu", "zip": "632004", "country": "India", "geoPoint": {"lat": 12.9184, "lon": 79.13255}}, {"facility": "Novo Nordisk Investigational Site", "city": "Johannesburg", "state": "Gauteng", "zip": "2001", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Novo Nordisk Investigational Site", "city": "Durban", "state": "KwaZulu-Natal", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Novo Nordisk Investigational Site", "city": "Durban", "state": "KwaZulu-Natal", "zip": "4126", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}]}, "referencesModule": {"references": [{"pmid": "21396703", "type": "RESULT", "citation": "Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7."}], "seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects underwent a run-in period of 3 weeks; 2 weeks of up-titration period, where metformin was up-titrated to 1500 or 2000 mg/day, followed by 1 week of maintenance period. Subjects who tolerated 1500 or 2000 mg/day of metformin for a week and had a median fasting plasma glucose \u2265 7.5 mmol/L (135 mg/dL) were randomised.", "recruitmentDetails": "There were 28 sites: Canada (4), India (4), South Africa (3) and the United States of America (17).", "groups": [{"id": "FG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "FG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "FG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "FG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "60"}, {"groupId": "FG002", "numSubjects": "62"}, {"groupId": "FG003", "numSubjects": "62"}]}, {"type": "Exposed", "achievements": [{"groupId": "FG000", "comment": "Three subjects withdrew prior to exposure to trial drug", "numSubjects": "58"}, {"groupId": "FG001", "comment": "One subject withdrew prior to exposure to trial drug", "numSubjects": "59"}, {"groupId": "FG002", "comment": "One subject withdrew prior to exposure to trial drug", "numSubjects": "61"}, {"groupId": "FG003", "comment": "One subject withdrew prior to exposure to trial drug", "numSubjects": "61"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "52"}, {"groupId": "FG001", "numSubjects": "51"}, {"groupId": "FG002", "numSubjects": "58"}, {"groupId": "FG003", "numSubjects": "56"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Non-Compliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "BG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "BG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "BG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "62"}, {"groupId": "BG004", "value": "245"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.9", "spread": "8.5"}, {"groupId": "BG001", "value": "55.3", "spread": "8.7"}, {"groupId": "BG002", "value": "54.4", "spread": "8.8"}, {"groupId": "BG003", "value": "53.1", "spread": "10.2"}, {"groupId": "BG004", "value": "54.2", "spread": "9.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "34"}, {"groupId": "BG003", "value": "25"}, {"groupId": "BG004", "value": "108"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "37"}, {"groupId": "BG004", "value": "137"}]}]}]}, {"title": "Glycosylated haemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated haemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.7", "spread": "1.1"}, {"groupId": "BG001", "value": "8.6", "spread": "1.2"}, {"groupId": "BG002", "value": "8.8", "spread": "1.1"}, {"groupId": "BG003", "value": "8.7", "spread": "1.1"}, {"groupId": "BG004", "value": "8.7", "spread": "1.1"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.6", "spread": "3.6"}, {"groupId": "BG001", "value": "9.9", "spread": "3.2"}, {"groupId": "BG002", "value": "10.6", "spread": "3.4"}, {"groupId": "BG003", "value": "9.8", "spread": "3.1"}, {"groupId": "BG004", "value": "10.2", "spread": "3.4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline in HbA1c after 16 weeks of treatment", "populationDescription": "The full analysis set (FAS) included all randomised subjects and missing data is imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.26", "spread": "1.11"}, {"groupId": "OG001", "value": "-1.28", "spread": "1.11"}, {"groupId": "OG002", "value": "-1.46", "spread": "1.06"}, {"groupId": "OG003", "value": "-1.49", "spread": "1.12"}]}]}]}, {"type": "SECONDARY", "title": "Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)", "description": "Mean of SMPG after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, before bedtime, at 4 am and before breakfast.", "populationDescription": "The full analysis set (FAS) included all randomised subjects and missing data is imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.30", "spread": "0.42"}, {"groupId": "OG001", "value": "8.55", "spread": "0.42"}, {"groupId": "OG002", "value": "8.45", "spread": "0.42"}, {"groupId": "OG003", "value": "8.42", "spread": "0.41"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Major and Minor Hypoglycaemic Episodes", "description": "Rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.", "populationDescription": "The full analysis set (FAS) included all randomised subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Episodes/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "62"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "221"}, {"groupId": "OG003", "value": "113"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Nocturnal Major and Minor Hypoglycaemic Episodes", "description": "Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 05:59 (included).", "populationDescription": "The full analysis set (FAS) included all randomised subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Episodes/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "62"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "17"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Treatment Emergent Adverse Events (AEs)", "description": "Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "61"}]}], "classes": [{"title": "Adverse events (AEs)", "categories": [{"measurements": [{"groupId": "OG000", "value": "594"}, {"groupId": "OG001", "value": "430"}, {"groupId": "OG002", "value": "488"}, {"groupId": "OG003", "value": "622"}]}]}, {"title": "Serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Severe AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "28"}]}]}, {"title": "Moderate AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "102"}, {"groupId": "OG002", "value": "110"}, {"groupId": "OG003", "value": "141"}]}]}, {"title": "Mild AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "468"}, {"groupId": "OG001", "value": "323"}, {"groupId": "OG002", "value": "379"}, {"groupId": "OG003", "value": "452"}]}]}, {"title": "Fatal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)", "description": "Mean values at Week -4 and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "61"}]}], "classes": [{"title": "ALAT, Week -4, N=56, 59, 62, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.6", "spread": "19.9"}, {"groupId": "OG001", "value": "29.2", "spread": "16.3"}, {"groupId": "OG002", "value": "30.9", "spread": "16.0"}, {"groupId": "OG003", "value": "32.9", "spread": "22.0"}]}]}, {"title": "ALAT, Week 16, N=53, 53, 58, 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.7", "spread": "13.1"}, {"groupId": "OG001", "value": "24.7", "spread": "14.4"}, {"groupId": "OG002", "value": "24.3", "spread": "13.0"}, {"groupId": "OG003", "value": "30.0", "spread": "25.3"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)", "description": "Mean values at Week -4 and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "61"}]}], "classes": [{"title": "ASAT, Week -4, N=56, 59, 62, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "26.7", "spread": "13.6"}, {"groupId": "OG001", "value": "22.5", "spread": "9.9"}, {"groupId": "OG002", "value": "23.9", "spread": "8.5"}, {"groupId": "OG003", "value": "24.2", "spread": "12.6"}]}]}, {"title": "ASAT, Week 16, N=53, 53, 58, 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.3", "spread": "10.0"}, {"groupId": "OG001", "value": "21.8", "spread": "7.7"}, {"groupId": "OG002", "value": "21.7", "spread": "7.7"}, {"groupId": "OG003", "value": "24.1", "spread": "13.7"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Serum Creatinine", "description": "Mean values at Week -4 and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "61"}]}], "classes": [{"title": "Creatinine, Week -4, N=56, 59, 62, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.5", "spread": "15.2"}, {"groupId": "OG001", "value": "75.4", "spread": "19.0"}, {"groupId": "OG002", "value": "73.2", "spread": "16.1"}, {"groupId": "OG003", "value": "72.4", "spread": "13.9"}]}]}, {"title": "Creatinine, Week 16, N=53, 53, 58, 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.1", "spread": "15.9"}, {"groupId": "OG001", "value": "76.6", "spread": "19.1"}, {"groupId": "OG002", "value": "71.5", "spread": "15.6"}, {"groupId": "OG003", "value": "74.2", "spread": "14.4"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Diastolic Blood Pressure (BP)", "description": "Mean values at baseline (Week 0) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "61"}]}], "classes": [{"title": "Week 0 (Baseline), N=57, 59, 62, 61", "categories": [{"measurements": [{"groupId": "OG000", "value": "81", "spread": "9"}, {"groupId": "OG001", "value": "82", "spread": "9"}, {"groupId": "OG002", "value": "80", "spread": "8"}, {"groupId": "OG003", "value": "79", "spread": "7"}]}]}, {"title": "Week 16, N=55, 55, 60, 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "79", "spread": "8"}, {"groupId": "OG001", "value": "82", "spread": "8"}, {"groupId": "OG002", "value": "78", "spread": "9"}, {"groupId": "OG003", "value": "77", "spread": "8"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Systolic Blood Pressure (BP)", "description": "Mean values at baseline (Week 0) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "61"}]}], "classes": [{"title": "Week 0 (Baseline), N=57, 59, 62, 61", "categories": [{"measurements": [{"groupId": "OG000", "value": "129", "spread": "14"}, {"groupId": "OG001", "value": "131", "spread": "13"}, {"groupId": "OG002", "value": "129", "spread": "15"}, {"groupId": "OG003", "value": "127", "spread": "14"}]}]}, {"title": "Week 16, N=55, 55, 60, 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "126", "spread": "14"}, {"groupId": "OG001", "value": "131", "spread": "15"}, {"groupId": "OG002", "value": "126", "spread": "16"}, {"groupId": "OG003", "value": "128", "spread": "13"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Pulse", "description": "Mean values at baseline (Week 0) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/minute", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}, {"groupId": "OG003", "value": "61"}]}], "classes": [{"title": "Week 0 (Baseline), N=57, 59, 62, 61", "categories": [{"measurements": [{"groupId": "OG000", "value": "79", "spread": "10"}, {"groupId": "OG001", "value": "79", "spread": "9"}, {"groupId": "OG002", "value": "79", "spread": "9"}, {"groupId": "OG003", "value": "76", "spread": "9"}]}]}, {"title": "Week 16, N=55, 55, 60, 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "77", "spread": "11"}, {"groupId": "OG001", "value": "78", "spread": "10"}, {"groupId": "OG002", "value": "79", "spread": "9"}, {"groupId": "OG003", "value": "74", "spread": "9"}]}]}]}, {"type": "SECONDARY", "title": "Physical Examination", "description": "Physical examination was performed at screening (Week -4), randomisation (Week 0) and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.", "reportingStatus": "POSTED", "timeFrame": "Week -4, Week 0, Week 8, Week 16", "groups": [{"id": "OG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted."}, {"id": "OG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}, {"id": "OG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted."}, {"id": "OG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "The adverse events were collected in a time frame of 16 weeks + 5 days follow up", "description": "Subjects in the safety analysis set contribute to the evaluation \"as treated\", hence the one subject who was treated with SIBA (D) 3W although he was randomised to SIBA (D) OD is analysed as SIBA (D) 3W for safety and as SIBA (D) OD in the FAS.", "eventGroups": [{"id": "EG000", "title": "SIBA (D)", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL \\[1 dosing unit = 9 nmol\\], insulin degludec; formulation D) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 units (U)/day and individually adjusted.", "seriousNumAffected": 1, "seriousNumAtRisk": 57, "otherNumAffected": 22, "otherNumAtRisk": 57}, {"id": "EG001", "title": "SIBA (E)", "description": "Soluble Insulin Basal Analogue E (SIBA E, 600 nmol/mL (1 dosing unit = 6 nmol), insulin degludec; formulation E) was given subcutaneously once daily (OD) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted.", "seriousNumAffected": 0, "seriousNumAtRisk": 59, "otherNumAffected": 16, "otherNumAtRisk": 59}, {"id": "EG002", "title": "SIBA (D) M, W, F", "description": "Soluble Insulin Basal Analogue D (SIBA D, 900 nmol/mL (1 dosing unit = 9 nmol), insulin degludec; formulation D) was given subcutaneously thrice weekly (Monday \\[M\\], Wednesday\\[W\\], Friday\\[F\\]) in the evening in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were were initiated at 20 U/day and individually adjusted.", "seriousNumAffected": 1, "seriousNumAtRisk": 62, "otherNumAffected": 19, "otherNumAtRisk": 62}, {"id": "EG003", "title": "IGlar", "description": "Insulin glargine (IGlar) was given subcutaneously once daily (OD) before bedtime in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were initiated at 10 U/day and individually adjusted.", "seriousNumAffected": 0, "seriousNumAtRisk": 61, "otherNumAffected": 23, "otherNumAtRisk": 61}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 61}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 61}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 5, "numAffected": 3, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 7, "numAffected": 6, "numAtRisk": 61}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 61}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 61}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 61}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 61}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 61}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 61}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 4, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 61}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 61}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 7, "numAffected": 5, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 9, "numAffected": 8, "numAtRisk": 61}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 3, "numAffected": 2, "numAtRisk": 61}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 6, "numAffected": 5, "numAtRisk": 61}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 61}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000049528", "term": "Insulin, Long-Acting"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M26073", "name": "Insulin, Long-Acting", "asFound": "Epinephrine", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}